Skip to main content

This website contains promotional content and is intended for Healthcare Professionals based in the United Kingdom only. Some content may only be relevant to HCPs practising in Great Britain (England, Scotland and Wales) according to product availability. This website is optimised for desktop use, and some features may perform differently on mobile devices.

Adverse event reporting can be found at the bottom of the page.

Home
Products
Stamaril® (Yellow Fever Vaccine Live) (yellow fever vaccine (live))

STAMARIL® (Yellow Fever Vaccine Live)

yellow fever vaccine (Live)

Summary

STAMARiL® is indicated for active immunization against yellow fever in persons:

  • travelling to, passing through or living in an area where there is a current or periodic risk of yellow fever transmission
  • travelling to any country that requires an International Certificate of Vaccination for entry (which may or may not depend on the previous itinerary)
  • handling potentially infectious materials (e.g. laboratory personnel).

Before you prescribe this vaccine please refer to the SmPC.1

Usage

Helps to protect against yellow fever from at least 10 days before travel for your traveller from 9 months of age1
AgeInitial doseBooster / revaccinationDuration of protection
From 9 months of age1, refer to current offical recommednations1 dose of 0.5ml of the reconstituted vaccine1Most do not need revaccination; refer to current offical recommednations1At least 10 years, may be lifelong1
In 2017 and 2018 we received 2 reports of fatal adverse reactions to the yellow fever vaccine (STAMARiL). Due to an increased risk of life-threatening reactions, the vaccine must not be given to anyone with a medical history of thymus dysfunction or who is immunosuppressed. In addition, extreme caution must be used and a careful risk assessment conducted before vaccination of people aged 60 years and older due to a substantially increased risk of such adverse reactions in this age group.1
In the most representative study in general population, the most frequently reported reactions (between 12% and 18% of subjects) were headache, asthenia, injection site pain and myalgia. In the most representative study in toddler population, the most frequently reported reactions (between 32% and 35% of toddlers) were irritability, crying and appetite loss. Adverse reactions usually occurred within the first three days following vaccination except pyrexia, which occurred between Day 4 and Day 14. For a full list of adverse reactions please refer to the product SMPC.

.

 
 
References
  1. Summary of Product Characteristics Stamaril UK

MAT-XU-2301130 (v3.0) Date of preparation: May 2025